Obesity
| Prediabetes
Obesity
Prediabetes
Impact of Oral Semaglutide 50 mg on Prediabetes According to Weight Loss Category: OASIS 1 Trial
book_2
Source:
ObesityWeek 2023 - Oral presentation
calendar_today
Published on Medfyle:
November 2023
import_contacts
5
min
In this medfyle
In participants with prediabetes and overweight/obesity from the OASIS 1 trial, compared to placebo oral semaglutide 50 mg improved glycemic control and reduced fasting serum insulin.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
This is a summary of a presentation given at the ObesityWeek®️ 2023.
The information and data provided is for information purposes only. The presenting author(s) of the original presentation had no involvement in the creation of this content.
©️2023 Infomedica-Medfyle. All rights reserved.
